Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Ascendia will provide services to support the clinical development of OA-201, a novel, injectable small molecule therapeutic for the treatment of symptomatic osteoarthritis pain.
Lead Product(s): OA-201
Therapeutic Area: Musculoskeletal Product Name: OA-201
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ampio Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2023
Details:
ASD-002 (clopidogrel) being developed by EmulSol nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval for Acute Coronary Syndrome.
Lead Product(s): Clopidogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ASD-002
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: AcuteBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023